Aller au contenu principal
xMedica

NCT07190300ClinicalTrials.gov

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination With Darolutamide Versus Darolutamide Alone in Patients With Metastatic Hormone-sensitive Prostate Cancer

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer (mHSPC). Phase I aims to determine the recommended dose(s)…

Phase 1 / Phase 2181 participants recherchés31 sites14 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2025-09-24; recorded start 2026-01-13
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 31 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 181 participants (target), run at 31 sites, across 14 countries.

How this score is built
  • Enrolment21/40

    181 participants (target)

  • Site count18/25

    31 sites

  • Country count12/15

    14 countries

  • Planned duration10/10

    Planned over about 80 months

  • Sponsor scale10/10

    Novartis Pharmaceuticals has led 1,104 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer (mHSPC). Phase I aims to determine the recommended dose(s) for expansion (RDE) of tulmimetostat in combination with darolutamide or abiraterone. Phase II is designed to further evaluate the efficacy and safety of tulmimetostat in combination with darolutamide compared with darolutamide alone in participants with mHSPC.

This is a Phase I/II, open-label, global, multicenter study evaluating tulmimetostat in combination with androgen receptor pathway inhibitors in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer (mHSPC). The study consists of two phases: Phase I (Dose Escalation) Phase I includes two treatment groups: 1. Group A (Part 1): tulmimetostat in combination with darolutamide. 2. Group B (Part 2): tulmimetostat in combination with abiraterone. The primary objective of Phase I is to determine the recommended dose(s) for expansion (RDE) of tulmimetostat in each combination regimen through a parallel dose-escalation design guided by a Bayesian Logistic Regression Model (BLRM). Enrollment will follow a staggered approach between the two groups. Participants may have received prior taxane-based chemotherapy and/or prior androgen receptor pathway inhibitor (ARPI) therapy and must not have received prior radioligand therapy. Participants will continue androgen deprivation therapy (ADT) to maintain castrate testosterone levels (\<50 ng/dL or \<1.7 nmol/L) according to investigator choice and local prescribing information. In Group B, abiraterone will be administered with prednisone or prednisolone according to local prescribing information. Phase II (Dose Expansion) Phase II is a randomized, open-label, multicenter dose-expansion study designed to further characterize the recommended dose(s) of tulmimetostat in combination with darolutamide and to provide proof-of-concept for the efficacy and safety of tulmimetostat plus darolutamide compared with darolutamide alone. Eligible participants are adult men with de novo or recurrent mHSPC who have not received prior radioligand therapy and may have received prior taxane-based chemotherapy and/or prior ARPI therapy (excluding darolutamide), with a maximum prior ARPI exposure of 4 months in the mHSPC setting. Participants will continue ADT throughout the study according to investigator choice and local prescribing information. Based on Phase I results, one or two tulmimetostat dose levels in combination with darolutamide may be evaluated. Study Duration and Follow-up For each participant, the study consists of a screening period, a treatment period, and post-treatment follow-up. Post-treatment follow-up includes: 1. A 30-day safety follow-up visit after permanent discontinuation of study treatment. 2. An efficacy follow-up period for participants who discontinue study treatment without documented disease progression or initiation of new anti-neoplastic therapy, including scheduled imaging assessments. 3. Long-term follow-up to collect survival status, new anti-neoplastic therapies, suspected treatment-related serious adverse events, and second primary malignancies. Participants will be contacted approximately every 12 weeks during the first 3 years and every 24 weeks thereafter until death, loss to follow-up, or withdrawal of consent. The study is designed to evaluate whether inhibition of EZH1/2 with tulmimetostat in combination with androgen receptor pathway inhibition may improve clinical outcomes in men with metastatic hormone-sensitive prostate cancer.

Affections

  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Éligibilité

Éligibilité
SexeHomme
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Key Inclusion Criteria: * Adult men ≥ 18 years old with de novo or recurrent mHSPC (without neuroendocrine or small cell features). The tumor lesion(s) may be located in the bone, soft tissue/visceral region, or both. * Participants must have castrate levels of testosterone, i.e., ≤ 50 ng/dL (≤ 1.7 nM). * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 * Adequate bone marrow and organ function * Prior ADT: Participants must have started ADT at least 1 month (at least 28 days) but no more than 12 months before study entry and be willing to continue ADT during treatment * Prior taxane use for mHSPC is permitted: * Phase I and II: Participants may have received, but not progressed on, one prior taxane-based therapy. * Phase II: Limited to 25% participants with prior taxane use. * Prior ARPI is allowed in both Phase I and Phase II: * Prior ARPI use in biochemical recurrence (BCR) or curative treatment is allowed for any duration, provided therapy was discontinued and participant had no evidence of conventional imaging positive metastatic disease at that time * Prior ARPI use in mHSPC is permitted but not mandated. If participants meet all study eligibility criteria, they are required to stop their prior ARPI after providing informed consent and remain off ARPI until Cycle 1 Day 1, when study treatment is initiated. * Phase I: Allowed for any duration. * Phase II: Allowed prior exposure to ARPI is ≤4 months. Participants with ongoing use of darolutamide are not eligible. Participants with ongoing ARPI are eligible for a switch from their ongoing ARPI therapy if they have not progressed to CRPC disease, and meet any of the criteria, indicative of suboptimal biochemical response, or intolerability, as assessed by the Investigator: * Evidence of insufficient PSA control or suboptimal PSA response, defined as PSA ≥ 0.2 ng/mL after 6-12 months ADT and no more than 4 months of current ARPI therapy in mHSPC with declining or stable PSA trend. Eligibility based on biochemical progression should be supported by objective evidence (e.g. PSA results). * Intolerance and non-compliance: Participant's inability to tolerate or comply with the prescribed ARPI. The site should maintain documentation to support the appropriateness of therapy changes resulting from intolerance or non-compliance. • Other permitted prior local therapy for mHSPC: * Phase I and II: Prior prostate-directed radiation or surgical intervention. Radiation must be completed before study entry; surgery at least 2 weeks prior. Key Exclusion Criteria: * Participants with evidence of mCRPC or biochemical recurrence / PSA only disease or asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy and with normal PSA for ≥ 1 year prior to the start of study treatment. * Participants who have not received ARPI treatment for mHSPC and present with PSA levels of ≤0.5 ng/mL or those with prior/ongoing ARPI treatment presenting with PSA levels of ≤ 0.2 ng/mL prior to treatment assignment/randomization. * Participants with CNS metastases are excluded unless: * they have received prior therapy (e.g. surgery, radiotherapy, gamma knife), are neurologically stable and asymptomatic. * they are not receiving corticosteroid for the purpose of maintaining neurologic integrity and have baseline and subsequent radiological imaging of the brain. * Concurrent use of first-generation anti-androgens (like bicalutamide). Prior use of a first-generation anti-androgen drug in the context of ADT initiation with a GNRH analog is allowed, provided it was administered for ≤14 days and the last dose was administered ≥7 days from the study entry. * Systemic ketoconazole is used as antineoplastic treatment for prostate cancer. * Previous exposure to radioligand therapy. * Treatment with any investigational agent within 28 days (or 5 half-lives, whichever is longer) prior to study entry. * Previous treatment with any Polycomb Repressive Complex 2 (PRC2) inhibitor, including but not limited to Enhancer of Zeste Homolog 2 (EZH2) inhibitors, EZH2/1 inhibitors, or embryonic ectoderm development (EED) inhibitors. * Herbal products that may decrease PSA levels within 4 weeks prior to the start of study drug treatment and while on study. * Participants taking prohibited medication(s) (e.g., strong CYP3A4 inducers or strong or moderate CYP3A4 inhibitors that cannot be stopped within 7 days or 5 half-lives (whichever is longer) prior to study treatment and for the duration of the study treatment or prohibited herbal product(s) that cannot be stopped 7 days prior to study treatment. * Have a history of a concurrent or second malignancy except for adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for ≥ 3 years. Participants with a history of leukemia/lymphoma and/or MDS are not eligible. Other inclusion/exclusion criteria may apply

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 1 / Phase 2
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuQUADRUPLE (4)
Recrutement181 participants recherchés

Promoteur et collaborateurs

  • Novartis Pharmaceuticals Promoteur

Groupes et interventions

  • Phase I: Group A (part 1)EXPERIMENTAL

    Tulmimetostat administered orally once daily (QD) at escalating dose levels in combination with darolutamide 600 mg orally twice daily (BID). Participants will continue androgen deprivation therapy (ADT) throughout the study.

  • Phase I: Group B (part 2)EXPERIMENTAL

    Tulmimetostat administered orally once daily (QD) at escalating dose levels in combination with abiraterone 1000 mg orally once daily (QD). Participants will continue androgen deprivation therapy (ADT). Abiraterone will be administered with prednisone/prednisolone according to local prescribing information.

  • Phase II: Arm 1EXPERIMENTAL

    Tulmimetostat Dose 1 orally once daily (QD) in combination with darolutamide 600 mg orally twice daily (BID). Participants will continue androgen deprivation therapy (ADT).

  • Phase II: Arm 2 (Optional)EXPERIMENTAL

    Tulmimetostat Dose 2 orally once daily (QD) in combination with darolutamide 600 mg orally twice daily (BID). Participants will continue androgen deprivation therapy (ADT). This arm will be included if two recommended dose(s) for expansion are selected from Phase I.

  • Phase II: Arm 3 (Control)ACTIVE_COMPARATOR

    Darolutamide 600 mg orally twice daily (BID). Participants will continue androgen deprivation therapy (ADT).

Interventions

  • Médicament Abiraterone

    Abiraterone 1000 mg administered orally once daily (QD) in combination with prednisone/prednisolone according to local prescribing information.

  • Médicament Androgen Deprivation Therapy (ADT)

    Background therapy consisting of a gonadotropin-releasing hormone (GnRH) agonist/antagonist or prior orchiectomy to maintain castrate testosterone levels (\<50 ng/dL \[\<1.7 nmol/L\]). All participants will continue ADT throughout study participation.

  • Médicament Darolutamide

    Darolutamide 600 mg administered orally twice daily (BID).

  • Médicament Prednisone/Prednisolone

    Oral corticosteroid administered with abiraterone in Phase I Group B according to local prescribing information.

  • Médicament Tulmimetostat

    Tulmimetostat is an oral dual EZH1/EZH2 inhibitor administered once daily. In Phase I, escalating dose levels will be evaluated in combination with darolutamide or abiraterone. In Phase II, one or two dose levels selected from Phase I will be evaluated in combination with darolutamide.

Critères de jugement

  1. Critère de jugement principal

    Phase I (Group A and Group B): Dose-limiting toxicities (DLTs)

    A dose-limiting toxicity was defined as an adverse event or abnormal laboratory value that was not clearly attributable to the underlying disease or an extraneous cause, occurred during the first 28 days of treatment with tulmimetostat, and met the protocol-defined dose-limiting toxicity criteria. Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. Dose-limiting toxicities were included in the Bayesian Logistic Regression Model used to support dose-escalation decisions.

    Délai From the first dose of study treatment through the end of Cycle 1, up to 28 days

  2. Critère de jugement principal

    Phase I (Group A and Group B): Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    The incidence, type, frequency, seriousness, and severity of adverse events and serious adverse events will be summarized. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.

    Délai From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months

  3. Critère de jugement principal

    Phase I (Group A and Group B): Number of Participants with dose adjustments

    The number of participants with dose reductions, dose interruptions, or permanent discontinuations, including the reasons for the dose adjustments, will be summarized by treatment group and dose cohort.

    Délai From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months

  4. Critère de jugement principal

    Phase I (Group A and Group B): Dose Intensity

    Dose intensity, calculated as the actual cumulative dose received divided by the actual duration of exposure, and relative dose intensity, calculated as the dose intensity divided by the planned dose intensity, will be summarized using descriptive statistics for each study drug.

    Délai From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months

  5. Critère de jugement principal

    Phase I (Group A and Group B): Duration of exposure to each study drug

    The duration of exposure, in months, to each study drug will be summarized using descriptive statistics by treatment group and dose cohort.

    Délai From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months

  6. Critère de jugement principal

    Phase II (Group A): Prostate-Specific Antigen (PSA) response rate of < 0.2 ng/mL at Month 6

    Prostate-Specific Antigen (PSA) response rate is defined as the proportion of participants who achieved a prostate-specific antigen level below 0.2 ng/mL at Month 6, confirmed by a second prostate-specific antigen assessment performed at least 3 weeks later.

    Délai At Month 6, with confirmation by a second prostate-specific antigen assessment performed at least 3 weeks later

  7. Critère de jugement secondaire

    Phase I (Group A): Plasma concentrations of Tulmimetostat and Darolutamide

    Plasma concentrations of tulmimetostat and darolutamide will be evaluated using pharmacokinetic samples collected from participants across the evaluated dose levels in Phase I, Group A.

    Délai Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Cycle 1, Day 2: 0 and 24 hours post-dose for tulmimetostat; Cycle 1, Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days

  8. Critère de jugement secondaire

    Phase I (Group A): AUC of Tulmimetostat and Darolutamide

    The area under the concentration-time curve from time zero to the last quantifiable concentration, the area under the concentration-time curve from time zero extrapolated to infinity, and the area under the concentration-time curve over a dosing interval at steady state will be derived, as applicable, and summarized using descriptive statistics.

    Délai Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Cycle 1, Day 2: 0 and 24 hours post-dose for tulmimetostat; Cycle 1, Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days

  9. Critère de jugement secondaire

    Phase I (Group A): Maximum Observed Plasma Concentration (Cmax) of Tulmimetostat and Darolutamide

    The maximum observed plasma concentration of tulmimetostat and darolutamide will be derived, as applicable, and summarized using descriptive statistics.

    Délai Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Cycle 1, Day 2: 0 and 24 hours post-dose for tulmimetostat; Cycle 1, Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days

  10. Critère de jugement secondaire

    Phase I (Group B): Plasma concentrations of Tulmimetostat and Abiraterone

    Plasma concentrations of tulmimetostat and abiraterone will be evaluated using pharmacokinetic samples collected from participants across the evaluated dose levels in Phase I, Group B.

    Délai Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Day 2: 0 and 24 hours post-dose; Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days.

  11. Critère de jugement secondaire

    Phase I (Group B): AUC of Tulmimetostat and Abiraterone

    The area under the concentration-time curve from time zero to the last quantifiable concentration, the area under the concentration-time curve from time zero extrapolated to infinity, and the area under the concentration-time curve over a dosing interval at steady state will be derived, as applicable, and summarized using descriptive statistics.

    Délai Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Day 2: 0 and 24 hours post-dose; Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days.

  12. Critère de jugement secondaire

    Phase I (Group B): Maximum Observed Plasma Concentration (Cmax) of Tulmimetostat and Abiraterone

    The maximum observed plasma concentration of tulmimetostat and abiraterone will be derived, as applicable, and summarized using descriptive statistics.

    Délai Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Day 2: 0 and 24 hours post-dose; Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days.

  13. Critère de jugement secondaire

    Phase II (Group A): Radiographic progression free survival (rPFS)

    Radiographic progression free survival (rPFS) is defined as the time from randomization to the first documented disease progression according to Prostate Cancer Working Group 3-modified Response Evaluation Criteria in Solid Tumors, version 1.1, as assessed by the investigator, or death from any cause, whichever occurred first.

    Délai From randomization until the first documented radiographic disease progression or death from any cause, whichever occurs first, assessed up to approximately 79 months

  14. Critère de jugement secondaire

    Phase II (Group A):Overall survival (OS)

    Overall survival (OS) is defined as the time from randomization to death from any cause.

    Délai From randomization until death from any cause, assessed up to approximately 79 months

  15. Critère de jugement secondaire

    Phase II (Group A): Objective Response Rate (ORR)

    Objective response (OR) is defined as the proportion of participants with a best overall response of confirmed complete response or partial response according to Prostate Cancer Working Group 3-modified Response Evaluation Criteria in Solid Tumors, version 1.1, as assessed by the investigator.

    Délai From randomization until disease progression, death, or the last adequate tumor assessment, assessed up to approximately 79 months

  16. Critère de jugement secondaire

    Phase II (Group A): Best Overall Response (BOR)

    Best Overall response (BOR) is defined as the best response recorded from the start of study treatment until disease progression or recurrence according to Prostate Cancer Working Group 3-modified Response Evaluation Criteria in Solid Tumors, version 1.1, as assessed by the investigator.

    Délai From randomization until disease progression or death from any cause, whichever occurred first, assessed up to approximately 79 months

  17. Critère de jugement secondaire

    Phase II (Group A): Duration of Response (DOR)

    Duration of response (DOR) is defined, for participants with a confirmed complete or partial response, as the time from the first documented response until the first documented disease progression according to Prostate Cancer Working Group 3-modified Response Evaluation Criteria in Solid Tumors, version 1.1, as assessed by the investigator, or death from any cause.

    Délai From the first documented complete or partial response until disease progression or death from any cause, whichever occurred first, assessed up to approximately 79 months

  18. Critère de jugement secondaire

    Phase II (Group A): Prostate-Specific Antigen 50 (PSA50) response rate

    Prostate-Specific Antigen 50 (PSA50) response is defined as a reduction of at least 50% from baseline in prostate-specific antigen at any post-baseline time point, confirmed by a second prostate-specific antigen assessment performed at least 3 weeks later.

    Délai From randomization until the last prostate-specific antigen assessment, assessed up to approximately 79 months

  19. Critère de jugement secondaire

    Phase II (Group A): Prostate-Specific Antigen (PSA) Response below 0.1 ng/mL

    Prostate-Specific Antigen (PSA) Response below 0.1 ng/mL is defined as achievement of a prostate-specific antigen level below 0.1 ng/mL at any post-baseline time point.

    Délai From randomization until the last prostate-specific antigen assessment, assessed up to approximately 79 months

  20. Critère de jugement secondaire

    Phase II (Group A): Time to castration-resistant prostate cancer (CRPC)

    Time to castration-resistant prostate cancer was defined as the time from randomization to the first occurrence of prostate-specific antigen progression, radiographic progression based on bone lesions, or radiographic progression based on soft-tissue or visceral lesions.

    Délai From randomization until prostate-specific antigen progression, radiographic progression in bone, or radiographic progression in soft-tissue or visceral lesions, whichever occurred first, assessed up to approximately 79 months

  21. Critère de jugement secondaire

    Phase II (Group A): Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    The analysis of adverse events will include categorization by type, frequency, and severity, as graded by the NCI CTCAE version 5.0.The incidence, type, frequency, seriousness, and severity of adverse events and serious adverse events will be summarized by treatment arm. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.

    Délai From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months

  22. Critère de jugement secondaire

    Phase II (Group A): Number of Participants with dose adjustments

    The number of participants with dose reductions, dose interruptions, or permanent discontinuations, including the reasons for the dose adjustments, will be summarized by treatment arm.

    Délai From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months

  23. Critère de jugement secondaire

    Phase II (Group A): Dose Intensity

    Dose intensity, calculated as the actual cumulative dose received divided by the actual duration of exposure, and relative dose intensity, calculated as dose intensity divided by planned dose intensity, will be summarized using descriptive statistics for each study drug and treatment arm.

    Délai From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months

  24. Critère de jugement secondaire

    Phase II (Group A): Duration of exposure to each study drug

    The duration of exposure, in months, to each study drug will be summarized using descriptive statistics by treatment arm.

    Délai From the first dose of study treatment through the 30-day safety follow-up, assessed up to approximately 79 months

  25. Critère de jugement secondaire

    Phase II (Group A): Plasma concentrations of tulmimetostat and darolutamide in participants included in intensive pharmacokinetic sampling

    Plasma concentrations of tulmimetostat and darolutamide will be evaluated in selected participants receiving tulmimetostat in combination with darolutamide.

    Délai Cycles 1 and 2, Day 1: 0, 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose; Cycle 1, Day 2: 0 and 24 hours post-dose for tulmimetostat; Cycle 1, Days 8 and 15: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days

  26. Critère de jugement secondaire

    Phase II (Group A): Plasma concentrations of Tulmimetostat

    Plasma concentrations of tulmimetostat will be evaluated using pharmacokinetic samples collected from participants receiving tulmimetostat across the evaluated Phase II dose levels.

    Délai Cycles 1 and 2, Day 1: 0 and 2 hours post-dose; Cycles 3 to 5, Day 1: pre-dose. Each cycle is 28 days

  27. Critère de jugement secondaire

    Phase II (Group A): Time to first symptomatic skeletal event (TTSSE)

    Time to first symptomatic skeletal event (TTSSE) is defined as the time from the first dose of study treatment to the first occurrence of a new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgery, radiation therapy to relieve bone pain, or death from any cause, whichever occurred first, as assessed by the investigator.

    Délai From the first dose of study treatment until the first symptomatic skeletal event, assessed up to approximately 79 months

Dates

Dates
Date de début13 janvier 2026 (réelle)
Achèvement principal2 août 2032 (estimée)
Achèvement2 août 2032 (estimée)
Première publication24 septembre 2025 (réelle)
Dernière mise à jour13 novembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisnovembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

29 sites sont en recrutement

Australia

Australia
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteCamperdownNew South WalesRetiré
Novartis Investigative SiteWollongongNew South WalesEn recrutement

Brazil

Brazil
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SitePorto AlegreRio Grande do SulEn recrutement

Canada

Canada
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteMontrealQuebecEn recrutement

China

China
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteGuangzhouEn recrutement

France

France
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteCréteilEn recrutement
Novartis Investigative SiteLilleEn recrutement
Novartis Investigative SiteNantesEn recrutement

Germany

Germany
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteEssenEn recrutement
Novartis Investigative SiteJenaThuringiaEn recrutement

Hong Kong

Hong Kong
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteHong KongEn recrutement

Hungary

Hungary
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteBudapestEn recrutement
Novartis Investigative SiteBudapestEn recrutement
Novartis Investigative SiteSzegedEn recrutement

Italy

Italy
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteRozzanoMIEn recrutement
Novartis Investigative SiteVeronaVRActif, sans recrutement

South Korea

South Korea
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteSeoulEn recrutement
Novartis Investigative SiteSeoulEn recrutement

Spain

Spain
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteMadridEn recrutement
Novartis Investigative SiteMadridEn recrutement
Novartis Investigative SiteMadridEn recrutement

Turkey (Türkiye)

Turkey (Türkiye)
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteAnkaraSihhiye AltindagEn recrutement

United Kingdom

United Kingdom
ÉtablissementVilleÉtat ou régionStatut
Novartis Investigative SiteLondonEn recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Univ of Alabama at BirminghamBirminghamAlabamaEn recrutement
Medical University of South Carolina MUSCCharlestonSouth CarolinaEn recrutement
Duke University Medical CenterDurhamNorth CarolinaEn recrutement
Uni Of Iowa Hospitals And ClinicsIowa CityIowaEn recrutement
Carolina Urologic Research CenterMyrtle BeachSouth CarolinaEn recrutement
Huntsman Cancer InstituteSalt Lake CityUtahEn recrutement
University of Kansas Cancer CenterWestwoodKansasEn recrutement
Wichita Urology Group PAWichitaKansasEn recrutement

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

Aucun changement n'a été enregistré depuis que nous avons intégré cette fiche pour la première fois.

Un changement est enregistré chaque fois que le promoteur met à jour la fiche du registre. Le statut, les dates, le recrutement et les sites apparaissent ici au fur et à mesure de leur évolution.